Tuesday, 22 October 2019

Lupin receives Health Canada approval for Propranolol Hydrochloride ER Capsules

16 September 2019 | News

Lupin is the first generic company to receive an approval for generic Inderal®-LA Capsules for the Canadian market

Pharma major Lupin Limited (Lupin) announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic Inderal®-LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 Facility.

Lupin’s Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal®-LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.

Propranolol Hydrochloride Extended-Release (ER) Capsules (Canadian Reference Product: Inderal®-LA Capsules) had an annual sales of approximately CAD 8.6 million.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account